Compare Medpace Holdings Inc (MEDP) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.79. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | QDTE | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $620.59 | $36.60 |
52-Week Low | $393.42 | $26.85 |
Enterprise Value | $16.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
QDTE trades at $29.80, up 0.51% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The fund faces scrutiny over its high distribution yield, which is reportedly funded by return of capital, leading to net asset value erosion. Recent news highlights underperformance in bull markets and concerns about the sustainability of its weekly payout strategy.
The outlook is cautious due to structural risks in the covered call strategy, with potential for continued NAV decline outweighing the attractive yield. Investors should weigh the income benefits against the risk of capital depletion, as analyst sentiment has turned negative with recent downgrades emphasizing the fund's vulnerability to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
